Article

Novel Hormone Therapy Combination Shown to Prolong Survival

A phase 3 randomized trial of two hormone therapies showed that in some postmenopausal women with hormone-positive metastatic breast cancer, the combo improves survival.

A phase 3 randomized trial of two hormone therapies, anastrozole and Faslodex (fulvestrant), showed that in some postmenopausal women with hormone-positive metastatic breast cancer, the combo improves survival.

Both are approved for women with hormone-positive metastatic breast cancer. Faslodex is used when the cancer has stopped responding to other hormonal therapies. Anastrozole is an aromatase inhibitor also approved to prevent breast cancer from recurring in women with early-stage disease.

The trial, which was presented a breast cancer conference in December, included 707 women who had not been previously treated for metastatic cancer. The combination improved median survival from 41.3 months to 47.7 months.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
Image of two doctors with text.
Imiage of two doctors with text.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.